*Corresponding Author: Dr. Indra Prasad Adhikari, Assistant Professor, Department of Biochemistry, SKS Hospital Medical College & Research Centre, Mathura, Uttar Pradesh, India. Email: harshaladhikari@gmail.com
Osteoporosis is a metabolic bone disease that, on a cellular level, results from osteoclastic bone resorption not compensated by osteoblastic bone formation. This causes bones to become weak and fragile, thus increasing the risk of fractures. Traditional pathophysiological concepts of osteoporosis focused on endocrine mechanisms such as estrogen or vitamin D deficiency as well as secondary hyperparathyroidism. However, research over the last decades provided exciting new insights into mechanisms contributing to the onset of osteoporosis, which go far beyond this. Bisphosphonates and parathyroid hormone (PTH) represent the antiresorptive and anabolic classes of drugs for osteoporosis treatment. Bone mineral density (BMD) is an essential parameter for the evaluation of anti-osteoporotic drugs. The aim of this study was to evaluate the effects of PTH versus bisphosphonates on BMD for the treatment of osteoporosis.
Keywords: Osteoporosis, bisphosphonates, parathyroid hormone, teriparatide, bone mineral density, fracture risk, systematic review.
How to cite this article: Sharma D, Kumar R, Jyoti A, Adhikari IP. Comparative study between bisphosphonates and PTH in osteoporosis: a systemic review article. Int J Drug Deliv Technol. 2026;16(3s): 713-721; DOI: 10.25258/ijddt.16.3s.88
Source of support: Nil.
Conflict of interest: None